Larotrectinib Demonstrates Limited Benefit in Patients with NTRK Alterations

This data analysis suggested that larotrectinib is highly effective in patients with NTRK gene fusions, however offered minimal benefit in patients with other non-fusion NTRK alterations.

Source: CancerNetwork - April 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news